Ftse Mib
38.171,72
-0,14%
DAX
22.660,98
0,24%
S&P 500
5.614,56
-2,70%
NASDAQ
17.468,32
0,00%
Bitcoin
81.766,87
4,20%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ iTeos Therapeutics Inc (ITOS) iTeos Therapeutics Inc (ITOS) Notizie

ITOS

iTeos Therapeutics (ITOS)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ITOS
DataOraFonteTitoloSimboloCompagnia
05/03/202513:14Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ITOSiTeos Therapeutics Inc
05/03/202513:06Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ITOSiTeos Therapeutics Inc
05/03/202513:00GlobeNewswire Inc.iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesNASDAQ:ITOSiTeos Therapeutics Inc
13/01/202513:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITOSiTeos Therapeutics Inc
10/01/202513:00GlobeNewswire Inc.iTeos Announces 2025 Strategic Priorities and Anticipated MilestonesNASDAQ:ITOSiTeos Therapeutics Inc
08/01/202513:00GlobeNewswire Inc.iTeos to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ITOSiTeos Therapeutics Inc
12/12/202414:55GlobeNewswire Inc.iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology CongressNASDAQ:ITOSiTeos Therapeutics Inc
07/12/202400:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ITOSiTeos Therapeutics Inc
26/11/202413:00GlobeNewswire Inc.iTeos to Participate in Upcoming Investor ConferencesNASDAQ:ITOSiTeos Therapeutics Inc
19/11/202415:57Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:ITOSiTeos Therapeutics Inc
12/11/202413:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ITOSiTeos Therapeutics Inc
12/11/202413:00GlobeNewswire Inc.iTeos Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:ITOSiTeos Therapeutics Inc
24/10/202413:00GlobeNewswire Inc.iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology CongressNASDAQ:ITOSiTeos Therapeutics Inc
21/10/202422:11Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ITOSiTeos Therapeutics Inc
14/09/202408:30GlobeNewswire Inc.iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer PatientsNASDAQ:ITOSiTeos Therapeutics Inc
20/08/202414:30GlobeNewswire Inc.iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024NASDAQ:ITOSiTeos Therapeutics Inc
08/08/202413:00GlobeNewswire Inc.iTeos Reports Second Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:ITOSiTeos Therapeutics Inc
05/08/202413:16Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ITOSiTeos Therapeutics Inc
05/08/202413:00GlobeNewswire Inc.iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical OfficerNASDAQ:ITOSiTeos Therapeutics Inc
08/07/202413:00GlobeNewswire Inc.iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSKNASDAQ:ITOSiTeos Therapeutics Inc
17/06/202415:00GlobeNewswire Inc.iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung CancerNASDAQ:ITOSiTeos Therapeutics Inc
10/05/202422:35Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ITOSiTeos Therapeutics Inc
10/05/202414:26GlobeNewswire Inc.iTeos Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:ITOSiTeos Therapeutics Inc
10/05/202414:24GlobeNewswire Inc.iTeos Therapeutics Announces $120 Million Registered Direct OfferingNASDAQ:ITOSiTeos Therapeutics Inc
07/04/202422:30GlobeNewswire Inc.iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024NASDAQ:ITOSiTeos Therapeutics Inc
06/03/202413:01GlobeNewswire Inc.iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of DirectorsNASDAQ:ITOSiTeos Therapeutics Inc
06/03/202413:00GlobeNewswire Inc.iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesNASDAQ:ITOSiTeos Therapeutics Inc
05/03/202422:30GlobeNewswire Inc.iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024NASDAQ:ITOSiTeos Therapeutics Inc
08/01/202413:00GlobeNewswire Inc.iTeos Announces 2024 Strategic Priorities and Anticipated MilestonesNASDAQ:ITOSiTeos Therapeutics Inc
03/01/202413:00GlobeNewswire Inc.iTeos to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ITOSiTeos Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ITOS

La tua Cronologia

BITI
ITLMS15
FTSE Italia All Share Te...
EU
CACTN
CAC All Trade Net Return
NYSE
HRB
H and R Block
TG
A2R839
Alstom
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci